# A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

> **NCT05043402** · PHASE3 · UNKNOWN · sponsor: **OncXerna Theraputics, Inc.** · enrollment: 400 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** navicixizumab
- **DEVICE:** Xerna™ TME Panel

## Key facts

- **NCT ID:** NCT05043402
- **Lead sponsor:** OncXerna Theraputics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-30
- **Primary completion:** 2023-11-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043402, "A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05043402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*